Loading... Please wait...

Our Newsletter

OSI-906 (Linsitinib) | IFG-1R/IR inhibitor

  • OSI-906 (Linsitinib).jpg
  • OSI-906 (Linsitinib), 400x400px, png
Catalog #:

Product Description

OSI-906 (Linsitinib) is an orally-available, ATP-competitive, imidazopyrazine-based dual inhibitor of IGF-R1 and IR with IC50 biochemical potency of 35 nM and 75 nM, respectively. [1] In vitro cell assays reveal that OSI-906 potently inhibits IGF-1R, pERK1/2, and p-70S6K at IC50s of 24, 28, and 60 nM, respectively. In HT-29 and Colo205 CRC cells, oSI-906 fully inhibits both IR and IGF-1R phosphorylation, with antiproliferative effects at EC50 of 210 nM and 320 nM, respectively.

Oral, in vivo efficacy studies (QDx12) of OSI-906 in a LISN xenograft model resulted in a dose-dependent effect on tumor growth inhibition with 100% TGI and 55% regression at 75 mg/kg, and 60% TGI at 25 mg/kg.

Technical information:

Chemical Formula:   C26H23N5O
CAS #:   867160-71-2
Molecular Weight:   421.49
Purity:   >98%
Appearance:   Yellow
Chemical Name:   (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
Solubility:   Up to 100 mM in DMSO
Synonyms:   OSI-906, OSI 906, OSI906, Linsitinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Mulvihill et al., Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 2009, 1(6), 1153-1171. Pubmed ID: 21425998

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the OSI-906 (Linsitinib) | IFG-1R/IR inhibitor to your wish list.

You Recently Viewed...